BackDaBomb Protein Biotech Overview

DaBomb Protein Biotech Receivables

Latest receivables for 6578.TWO: $46M.

Get informed when a big investor buys or sells

+ Follow
Receivables
$45.90M
↑ 38.61% YoYΔ $12.78M vs prior year quarter

Peer trimmed avg / median

Loading

DaBomb Protein Biotech Receivables History

Loading

DaBomb Protein Biotech vs. peers: Receivables Comparison

Loading

DaBomb Protein Biotech Receivables Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

DaBomb Protein Biotech (6578.TWO) FAQ

As of the most recent data (September 2026), 6578.TWO shows a receivables of $46M. That compares with $33M in the prior-year period — up 38.6% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, 6578.TWO's receivables is now $46M (was $33M) — a 38.6% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether DaBomb Protein Biotech is outperforming or lagging.

Tracking 6578.TWO's receivables over time shows whether DaBomb Protein Biotech is scaling, shrinking, or reshaping that part of the business. The current reading is $46M That compares with $33M in the prior-year period — up 38.6% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this receivables page, Stockcircle has DaBomb Protein Biotech's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect receivables (currently $46M) with ownership activity and broader fundamentals.